Skip to main content
PMC home page
Springer logoLink to Springer
. 2019 Nov 15;64(9):1261–1271. doi: 10.1007/s00038-019-01298-x

Cost-effectiveness of precision medicine: a scoping review

Miriam Kasztura 1,✉,#, Aude Richard 2,#, Nefti-Eboni Bempong 2, Dejan Loncar 2, Antoine Flahault 2
PMCID: PMC6867980  PMID: 31650223

Abstract

Objectives

Precision medicine (PM) aims to improve patient outcomes by stratifying or individualizing diagnosis and treatment decisions. Previous reviews found inconclusive evidence as to the cost-effectiveness of PM. The purpose of this scoping review was to describe current research findings on the cost-effectiveness of PM and to identify characteristics of cost-effective interventions.

Methods

We searched PubMed with a combination of terms related to PM and economic evaluations and included studies published between 2014 and 2017.

Results

A total of 83 articles were included, of which two-thirds were published in Europe and the USA. The majority of studies concluded that the PM intervention was at least cost-effective compared to usual care. However, the willingness-to-pay thresholds varied widely. Key factors influencing cost-effectiveness included the prevalence of the genetic condition in the target population, costs of genetic testing and companion treatment and the probability of complications or mortality.

Conclusions

This review may help inform decisions about reimbursement, research and development of PM interventions.

Electronic supplementary material

The online version of this article (10.1007/s00038-019-01298-x) contains supplementary material, which is available to authorized users.

Keywords: Precision medicine, Economic evaluation, Scoping review

Introduction

Over the last several decades, a gradual shift toward patient-centered healthcare opened the door for individualized approaches to diagnostics and treatment. Precision medicine (PM) provides “timely and cost-effective medical solutions to stratified patient subpopulations with predictable outcome margins” (Akhmetov and Bubnov 2015). The European Union’s Horizon 2020 Advisory Group defines PM as the “characterization of individuals’ phenotypes and genotypes (e.g., molecular profiling, medical imaging and lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention” (European Commission 2013; Nimmesgern et al. 2017).

Nowadays, PM interventions consist mostly of genetic profiling, including the detection of predictive biomarkers. These can identify patients at risk for a specific disease or a severe variant of a disease and allow for preventive interventions to reduce the burden of diseases and improve quality of life. Predictive biomarkers can also identify patients who will benefit most from certain treatments (Waldman and Terzic 2008). Furthermore, the detection of germline variations such as drug-metabolizing enzymes can help identify individuals at greater risk of adverse events or who would benefit most from dose adjustments to optimize safety (Shabaruddin et al. 2015; Waldman and Terzic 2008). Today, there are over 54,000 diagnostic tests available for over 16,400 genes (NCBI. GTR: genetic testing registry 2017). PM has the potential to reduce costs associated with inappropriate, often expensive pharmacological treatments, as well as hospitalizations for serious adverse drug reactions (Berm et al. 2016), and could ultimately allow for a more effective use of healthcare resources (Shabaruddin et al. 2015).

The cost-effectiveness of targeted interventions depends on many factors, such as the prevalence of a certain gene or allele in a population, the accuracy of a test and the costs of testing and personalized treatment (Hatz et al. 2014). As a result, patient outcomes may improve, and however, the cost-effectiveness of PM remains unclear. Recently, experts have suggested a value-based approach to PM (Patrinos and Mitropoulou 2017; Shabaruddin et al. 2015). This means measuring the value of PM interventions and demonstrating their cost-effectiveness to inform policy decisions about reimbursement and investment in research and development, particularly in solidarity-based health systems.

Economic evaluations

Economic evaluations “identify, measure, value and compare the benefits to the costs of the alternatives being considered” (Drummond et al. 2015), both in terms of cost and outcomes, and combine them in analytical models to determine the cost per quality-adjusted life year (QALY) gained through a specific intervention compared with a standard of care (Terkola et al. 2017). In other words, a cost-effectiveness analysis evaluates if the improvement in clinical outcomes that an intervention provides is enough to justify the additional amount of money spent on it. It does not determine if an intervention reduces cost, but it tells us which intervention provides better value for the same amount of money spent (Institute of Medicine 2013). As explained in the proceedings of a workshop held by the Institute of Medicine (2013) “the best result is when outcomes improve and costs go down. The worst is when outcomes become worse and costs increase. Most (PM) interventions in healthcare result in higher costs with improved outcomes”.

Another important point to consider is the perspective adopted by different economic analyses. The models can incorporate data ranging from clinical to financial and humanistic, and include direct and indirect costs. The type of cost data included depends on the perspective adopted by the study (Lieberthal 2013). A payer perspective usually determines cost-effectiveness by comparing cost per quality-adjusted life year (QALY) gained, with a currently accepted threshold of “willingness-to-pay”. Studies adopting a societal perspective further include opportunity costs, such as out-of-pocket patient costs, other indirect medical costs, but also loss of income or productivity (Lieberthal 2013).

Previous systematic reviews

In the past ten years, several systematic reviews of economic evaluations of PM and pharmacogenomics have been published (Berm et al. 2016; D’Andrea et al. 2015; Grosse 2015; Hatz et al. 2014; Plumpton et al. 2016; Rosso et al. 2017; Verbelen et al. 2017). Each generally examined a narrow field of PM: Verbelen or Plöthner (Plothner et al. 2016; Verbelen et al. 2017), for instance, looked at pharmacogenetic guided treatment, whereas Rosso, Grosse or Buchanan examined specific diseases or risk factors (e.g., hypercholesteremia) (Buchanan et al. 2017; Grosse 2015; Rosso et al. 2017) or adverse drug reactions in the case of Plumpton (Plumpton et al. 2016).

Most previous systematic reviews found inconclusive evidence regarding the cost-effectiveness of PM, mainly due to the insufficient quality of the studies included. The main points of criticism in this regard were inadequate sensitivity analyses, generally poor methodology, inconsistencies due to a lack of clinical evidence and low quality of data used to populate economic models, as well as heterogeneity between study designs, models and populations (Berm et al. 2016; Hatz et al. 2014; Phillips et al. 2014; Ross et al. 2012; Vegter et al. 2010). Nonetheless, a recent study reported an improvement in the quality of economic evaluations over the last few years (Shabaruddin et al. 2015). Another recommendation from previous reviews was to identify which factors influence the cost-effectiveness of PM interventions (Hatz et al. 2014). A scoping review of economic evaluations of PM could, therefore, help identify common factors and strategies for an increasingly efficient application of PM, across all fields of PM.

Aim and research question

Our aim was to describe current research findings on the cost-effectiveness of PM and to identify characteristics of better cost-effectiveness. Specifically, we aimed to answer the following questions:

  1. What is known from existing literature about the cost-effectiveness of PM?

  2. Which factors influence the cost-effectiveness of PM?

Methods

A scoping review aims to describe, summarize and facilitate dissemination of research findings. Scoping reviews provide a narrative and descriptive account of available research (Arksey and O’Malley 2005). For this scoping review, we applied the following definition of precision medicine: “clinical, therapeutic and diagnostic approaches to optimal disease management based on individual variations in a patient’s genetic profile” (U.S. National Library of Medicine 2017). PRISMA guidelines were adhered to where applicable (Moher et al. 2009).

Search criteria

We used a combination of search terms based on previous reviews and aligned with the definition of PM used for this study, aiming to capture a broad range of results (Berm et al. 2016; Hatz et al. 2014; Plumpton et al. 2016; Wong et al. 2010). Keywords such as “personalized medicine”, “precision medicine” and “pharmacogenomics” were combined with search terms related to economic evaluations (Fig. 1). PubMed was chosen for the search, as it indexes the largest number of journals relevant to PM (Cesuroglu et al. 2016).

Fig. 1.

Fig. 1

Open in a new tab

Search strategy

Inclusion and exclusion criteria

In the interest of time efficiency, we only included studies published after January 2014. Several systematic reviews have been published, which include pre-2014 articles. Also, by excluding older studies, which have often been reported to lack quality (Shabaruddin et al. 2015; Wong et al. 2010), we hoped to maximize the quality of the studies included.

Further, in our initial literature search, not limited in time, it became evident that over half of the studies were published after 2014. As a scoping review aims to capture the broadest range of studies, and considering that the systematic review using the most similar range (if not the method), included studies up to 2013 (Hatz et al. 2014), we settled on studies published after January 2014.

Studies were included if they were published between January 2014 and November 2017, from a field of PM as defined for this review, evaluating economic outcomes, written in English, French or German, and full text was accessible. Articles were first screened on the title. If the title was not informative enough to form a decision with respect to these criteria, abstracts were assessed. Additional articles were identified through reference tracking.

Data extraction

From the selected studies, the following data were extracted: (I) year of publication, (II) type disease or medical condition, (III) country, (IV) characteristics of economic analysis (type, perspective, ICER, WTP threshold applied, whenever this information was available), (V) results, (VI) conclusion of the authors, (VII) sponsorship and/or declared conflict of interest and (VII) factors influencing cost-effectiveness (see Online Resource 1). For interpretation of the outcome measure (i.e., cost-effectiveness), the conclusions as reported by the authors were used (see Online Resource 1). Two reviewers collaborated, and any disagreement was resolved in consensus.

Results

From over 1900 results in the initial PubMed search combined with a manual reference search, a total of 83 studies were selected (see Online Resource 1 for full list). Reasons for exclusion were articles not concerned with PM as defined for this review; “opinion” articles; no economic analysis or absence of comparator; discussion of economic models/R&D only; and publication date before January 2014 and duplicates (Fig. 2).

Fig. 2.

Fig. 2

Open in a new tab

PRISMA flowchart showing the number of studies at each stage of the review process

General characteristics

Geographical distribution

Since 2014, most economic evaluations of PM have been conducted in Europe and North America, with a slightly higher number in Europe (31%) (Table 1).

Table 1.

General characteristics of included studies

Geographical distribution N % of total (N = 83)
Total Europe 26 31
Total Asia and Oceania 16 19
Total North America 23 28
Systematic reviews 13 16
n/a 5 6
Disease type N % of total (N = 83)
Cancer 36 43
Cardiovascular diseases 23 28
Adverse drug reaction 9 11
Systematic reviews covering several areas 4 5
Other (total) 11 13
 Other: mental health 2
 Other: ophthalmic disease (macular degeneration) 1
 Other: autism 1
 Other: auto-immune diseases 3
 Other: MODY 2
 Other: HIV 1
 Other: asthma 1
Open in a new tab

Disease type

The most frequent PM interventions included in this review related to cancer (43% of studies, N = 36) and cardiovascular diseases (28% of studies, N = 23) and adverse drug reactions (11% of studies, N = 9). Some other diseases were studied less frequently (13%, N = 11), and some systematic reviews covered several disease types (5% of studies, N = 4) (Table 1).

Genetic or pharmaceutical industry involvement

A total of 37% (N = 31) studies were either industry sponsored, or one or more authors were employed or financially supported by either pharmaceutical industry or industry involved in genetic testing or other areas of personalized medicine (see Online Resource 1).

Economic characteristics

Type of economic analyses

Of the 83 studies included, 75% (N = 62) were cost-effectiveness analyses and 5% (N = 4) were cost-utility studies (Table 2). The remaining 20% (N = 17) used different methods, cost calculations or were systematic reviews.

Table 2.

Economic characteristics of included studies

Type of analysis N % of total (N = 83)
Cost-effectiveness analysis 62 75
Cost-utility analysis 4 5
Other 17 20
Conclusion of authors on cost-effectiveness N % of total (N = 83)
Cost saving 2 2
Cost-effective 57 69
Inconclusive 9 11
Not cost-effective 14 17
n/a 1 1
Perspective of economic evaluations N % of total (N = 83)
Missing 11 13
n/a (SystRev or other) 16 19
Payer 20 24
Healthcare system 23 28
Societal 7 8
Healthcare system and societal 5 6
Societal and payer 1 1
Open in a new tab

Perspective

As seen in Table 2, around one-fifth (13%, N = 11) of the included studies did not provide information on the perspective chosen. Another 19% (N = 16) were systematic reviews or other types of review articles. The remaining studies provided information on perspective, of which 24% (N = 20) adopted a payer’s perspective, 28% (N = 23) used the perspective of the healthcare system and 8% (N = 7) took a societal perspective. Six percent of the studies (N = 5) conducted the evaluation from both a healthcare system and societal perspective, and 1% (N = 1) used a payer and societal perspective.

Cost-effectiveness: conclusion of authors

A large majority of studies (N = 59) conclude that the PM intervention is at least cost-effective compared to usual care (see Table 2). However, the applied willingness-to-pay thresholds vary widely, from USD 20,000/QALY, mainly in studies from the UK or Europe, to USD 200,000/QALY in studies conducted in the USA. This means that a PM intervention considered cost-effective in the USA would not necessarily fulfill the criteria to be considered so in Europe, as the amount of money per QALY, a society is willing to spend is variable.

Factors influencing cost-effectiveness

One of the main limitations cited by authors was the insufficient quality of the data used to populate the models. Similarly, all systematic reviews report the difficulty to compare different economic analyses due to methodological inconsistencies and the heterogeneity of data included in the models. Nevertheless, similarly to others before us (Ademi et al. 2017), we noted that there were key factors that influenced the cost-effectiveness of PM. Out of all studies, 53 studies found that one or more factors influenced the cost-effectiveness of PM in their models (Table 3). The main factors, which influence cost-effectiveness, were found to be the prevalence of the genetic “condition” in the target population, costs of genetic testing and companion treatment and the probability of complications or mortality.

Table 3.

Factors influencing cost-effectiveness

Prevalence of “allele” in population
Ademi et al. (2017), Alagoz et al. (2016), Barzi et al. (2015), Chen et al. (2016), D’Andrea et al. (2015, 2016), Dong et al. (2015), Gallego et al. (2015), Gonzalez et al. (2015), Grosse (2015), Ke et al. (2017), Lee et al. (2014), Moretti et al. (2017), Naylor et al. (2014), Nguyen et al. (2017), Patel et al. (2014), Plothner et al. (2016), Ruiz-Iruela et al. (2016) and Snowsill et al. (2017)
Probability of complications (incl. mortality)
Alagoz et al. (2016), Chong et al. (2014), Gallego et al. (2015), Gonzalez et al. (2015), Goverde et al. (2016), Jahn et al. (2015, 2017), Ke et al. (2017), Li et al. (2017), Moretti et al. (2017), Patel et al. (2014), Pink et al. (2014), Plumpton et al. (2015), Saokaew et al. (2014), Schremser et al. (2015), Snowsill et al. (2017) and You (2014)
Cost of genetic testing
Ademi et al. (2017), Alagoz et al. (2016), Barzi et al. (2015), Chong et al. (2014), D’Andrea et al. (2016), Dong et al. (2015), Green et al. (2014), Grosse (2015), Li et al. (2017), Martes-Martinez et al. (2017), Naylor et al. (2014), Nguyen et al. (2017), Plothner et al. (2016), Rubio-Terres et al. (2015), Snowsill et al. (2017), Wang et al. (2017) and Snowsill et al. (2015)
Cost of companion treatment
Buchanan et al. (2017), Gallego et al. (2015), Horster et al. (2017), Jahn et al. (2015), Lim et al. (2016), Lu et al. (2016), Narita et al. (2015), Patel et al. (2014), Ruiz-Iruela et al. (2016), Schackman et al. (2015), Yamauchi et al. (2014), You (2014, 2015) and Wallbillich et al. (2016)
Age at testing, stage of disease
Buchanan et al. (2017), Green et al. (2014), Jahn et al. (2015), Manchanda et al. (2015), Schremser et al. (2015) and Yamauchi et al. (2014)
Effectiveness of test (accuracy)
Martes-Martinez et al. (2017), Plothner et al. (2016) and Snowsill et al. (2017)
Other (utility/quality of life (QoL) after preventive treatment, patient adherence to treatment, uptake of genetic testing, impact of genetic testing on QoL)
Balentine et al. (2017), Green et al. (2014), Lu et al. (2016), Martes-Martinez et al. (2017), Plothner et al. (2016), Shiffman et al. (2015), Snowsill et al. (2014, 2015, 2017), Verhoef et al. (2016) and Plumpton et al. (2016)
Open in a new tab

Prevalence of the “allele” or “mutation” in the population tested

The prevalence of an allele of interest influences the positive predictive value of the genetic test (Ademi et al. 2017; Alagoz et al. 2016; D’Andrea et al. 2016; Gonzalez et al. 2015; Grosse 2015; Ke et al. 2017; Lee et al. 2014; Moretti et al. 2017; Naylor et al. 2014; Plothner et al. 2016; Ruiz-Iruela et al. 2016; Snowsill et al. 2017). This, therefore, increases the effectiveness of “cascade” screening programs where, for example, an individual is identified by clinical prescreening as having an increased risk of having the allele/mutation (Ademi et al. 2014; Lazaro et al. 2017).

Probability of complications

A higher probability of complications (including mortality) will decrease the cost-effectiveness of a PM intervention (Alagoz et al. 2016; Chong et al. 2014; Gonzalez et al. 2015; Jahn et al. 2015, 2017; Ke et al. 2017; Moretti et al. 2017; Pink et al. 2014; Plumpton et al. 2015; Saokaew et al. 2014; Schremser et al. 2015; Snowsill et al. 2017) by decreasing the number of life years gained. For the same reason, factors such as age at testing (Buchanan et al. 2017; Green et al. 2014; Jahn et al. 2015; Manchanda et al. 2015), as well as the stage of the disease (Schremser et al. 2015), will have the same effect. A person with end-stage metastatic cancer might still benefit from a PM intervention, but the cost-effectiveness ratio will be much lower, as the potential benefit is smaller. Therefore, it is more cost-effective to identify a risk or a susceptibility to a specific treatment in a younger person and/or at an earlier stage of disease.

Cost of genetic testing

Another factor identified in our review as a barrier to cost-effectiveness of PM interventions is the high cost of some genetic tests (Ademi et al. 2017; Alagoz et al. 2016; Chong et al. 2014; Green et al. 2014; Grosse 2015; Martes-Martinez et al. 2017; Naylor et al. 2014; Nguyen et al. 2017; Plothner et al. 2016; Rubio-Terres et al. 2015; Wang et al. 2017). However, it has been observed that the cost of genetic testing has been decreasing and is expected to continue to do so in the future (National Institute of Health NIH 2016).

The cost of treatment, if the treatment is a “companion” treatment, also influences the cost-effectiveness of PM (Buchanan et al. 2017; Horster et al. 2017; Jahn et al. 2015; Lim et al. 2016; Ruiz-Iruela et al. 2016). A companion treatment is marketed together with a specific genetic test. This is particularly relevant in oncology, where cancer “companion” treatments can have a very high cost.

Accuracy of the genetic test

Some studies included in our scoping review noted that the accuracy of a genetic test can influence the cost-effectiveness of PM (Martes-Martinez et al. 2017; Plothner et al. 2016; Snowsill et al. 2017). Indeed, sensitivity and specificity can play an important role in the cost-effectiveness of testing, as do the cost of false-positive or false-negative results and the unnecessary treatments and/or mortality and morbidity associated with them.

Other factors

Finally, factors such as the health-related quality of life (HRQoL) during and after a preventive treatment, the timeframe when a risk factor was identified, patient adherence to treatment, the uptake of genetic testing in situations of hereditary risk factors and the impact of genetic testing on HRQoL were also identified as having a potential impact on the cost-effectiveness of PM (Balentine et al. 2017; Green et al. 2014; Martes-Martinez et al. 2017; Plothner et al. 2016; Shiffman et al. 2015; Snowsill et al. 2017; Verhoef et al. 2016). Most of these factors have been previously identified, and our findings reinforce results from previous reviews (Beaulieu et al. 2010; Berm et al. 2016; Ferrusi et al. 2009; Goldie and Levin 2001; Husereau et al. 2014; Institute of Medicine 2013; Veenstra et al. 2000).

Discussion

This study aimed to describe previous research findings on the cost-effectiveness of PM and to identify factors that influence the cost-effectiveness of PM. This scoping review described 83 studies relevant to economic evaluations and cost-effectiveness of a broad range of precision medicine interventions. Whereas most previous reviews found an overwhelming majority of studies originating from the USA (Hatz et al. 2014), we found that, since 2014, most economic evaluations of PM have been conducted in Europe and North America, with a slightly higher number in Europe (31%).

Perspectives

In the most recent literature, there seems to be a move away from cost and toward a focus on value. Measuring the value of PM is urgently needed (Terkola et al. 2017). However, the classic economic principles—association between cost and benefits are not easily measurable in health care. Until recently, patients were not able to choose what kind of healthcare they received, nor did they pay out of their own pocket (Institute of Medicine 2013). Within privatized health insurance systems, however, patients must assume out-of-pocket costs depending on their deductible or may decide to cover a treatment that is not validated and therefore not reimbursed by their insurance. Further, patients as healthcare consumers are more aware of the options available for specific treatments or interventions, as well as potential harm and benefits of an intervention.

Some authors argue that current health economics approaches are limited, as they do not fully capture the different perspectives of value in health (Grosse et al. 2008; Institute of Medicine 2013; Terkola et al. 2017). The conversation around different financing options in healthcare, including personalized medicine, is ongoing.

Furthermore, the comparison baseline has changed. Whereas previously the comparison was between “genetic testing” and “no testing”, nowadays usual care already includes testing. For example, as Berm et al. (2016) describe KRAS testing before treatment with cetuximab in colorectal cancer, it was compared to no testing before treatment. Testing before treatment was found to be superior and was included in clinical guidelines, de facto becoming the new “usual” care. Thereafter, new treatment options will be compared to the combination of KRAS testing before cetuximab administration (Berm et al. 2016).

Challenges for economic evaluations in precision medicine

Many challenges for economic evaluations in PM have previously been described (Faulkner et al. 2012; Hatz et al. 2014; Terkola et al. 2017). Economic models have significant limitations compared with clinical trials. Data from clinical trials, which are usually extrapolated to populate the models, may not be transferable into a real-world setting (Lieberthal 2013). Further, the increasing complexity of PM interventions, such as sequential or cascade testing, which is reflected in the models, results in a higher level of uncertainty about the incremental cost-effectiveness ratio (ICER) (Terkola et al. 2017).

Lack of data

There is still a lack of clinical evidence to support PM technologies, particularly of “real-world” data on clinical utility, which is not model based or derived from selective trials (Akhmetov and Bubnov 2015; Berm et al. 2016; Brüggenjürgen et al. 2012; Phillips et al. 2014; Terkola et al. 2017). There is an even larger uncertainty with pharmacogenomic tests, since they have no direct influence on patient outcomes, as they do not treat patients directly, but rather improve a clinician’s decisions about treatment (Akhmetov and Bubnov 2015).

As with clinical data, there is a lack of real-world cost data, and of data where opportunity costs are reflected (e.g., the costs for genetic counseling and the costs of ambiguous test results) (Conti et al. 2010).

Besides this, several authors have raised the issue of cost for testing inaccuracies (Conti et al. 2010; Goldie and Levin 2001; Terkola et al. 2017). It is argued that for a cost-effectiveness analysis to be useful to inform policies, it should include all clinical and economical events triggered by the test results, such as the cost of false-positive and false-negative results. In an example explained by Goldie (Goldie and Levin 2001), for a woman who tests positive for the BRCA-1 mutation but is not destined to develop breast cancer (estimated at 30%), the benefits of a prophylactic mastectomy would be negligible but she would still bear the huge costs of the psychological anxiety and healthcare resources associated with lifelong screening.

“Willingness-to-pay” thresholds

As our review demonstrates, there is no consensus on a willingness-to-pay threshold for a quality-adjusted life year gained. In the USA, the most commonly used willingness-to-pay threshold is 50,000 USD per QALY, historically based on the cost-effectiveness of dialysis from the 1970s, whereas currently, the cost-effectiveness ratio of dialysis is 130,000 USD per QALY (Coate and Leighl 2011). WHO recommends a willingness-to-pay threshold of 3 times the GDP of the country. This threshold, however, was only applied in 3 out of 83 studies included in this scoping review (Brown et al. 2015; Horster et al. 2017; Schremser et al. 2015). It also has been noted that QALYs lack the ability to fully capture all aspects of health outcomes (Garrison et al. 2017; Terkola et al. 2017).

Limitations of this study

This scoping review has several limitations. First, we only searched one database, which reduces the potential breadth and depth of the results. Second, the chosen definition of PM (narrower, e.g., no lifestyle, nor prenatal diagnostics included) and search terms (searching for articles identified as “personalized” or “precision” medicine) did not include all individual genetic tests. This has the potential to limit the scope of the results.

Conclusion

PM interventions have been increasingly useful for screening, testing and treatment of many diseases. Due to the many factors which influence cost-effectiveness and the varied thresholds of willingness-to-pay applied, the cost-effectiveness of PM remains unclear. Therefore, we might require a different approach to value precision medicine interventions.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 132 kb) (132.3KB, pdf)

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Footnotes

We thank the International Risk Governance Center (IRGC) for its support to this initiative and the research project which has been discussed and presented to its scientific committee and in a satellite event of the Geneva Health Forum, organized in April 2018 at the Campus Biotech, EPFL, Geneva.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Miriam Kasztura and Aude Richard have contributed equally to this work.

References

  1. Ademi Z, Watts GF, Pang J, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol. 2014;8:390–400. doi: 10.1016/j.jacl.2014.05.008. [DOI] [PubMed] [Google Scholar]
  2. Ademi Z, Sutherland CS, Van Stiphout J, et al. A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives. J Thromb Thrombolysis. 2017;44:494–506. doi: 10.1007/s11239-017-1554-5. [DOI] [PubMed] [Google Scholar]
  3. Akhmetov I, Bubnov RV. Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA J. 2015;6:19. doi: 10.1186/s13167-015-0041-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Alagoz O, Durham D, Kasirajan K. Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions. Pharmacogenom J. 2016;16:129–136. doi: 10.1038/tpj.2015.39. [DOI] [PubMed] [Google Scholar]
  5. Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32. doi: 10.1080/1364557032000119616. [DOI] [Google Scholar]
  6. Balentine CJ, Vanness DJ, Schneider DF. Cost-effectiveness of lobectomy versus genetic testing (Afirma(R)) for indeterminate thyroid nodules: considering the costs of surveillance. Surgery. 2017 doi: 10.1016/j.surg.2017.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Barzi A, Sadeghi S, Kattan MW, Meropol NJ. Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst. 2015 doi: 10.1093/jnci/djv005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Beaulieu M, de Denus S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010;11:1573–1590. doi: 10.2217/pgs.10.145. [DOI] [PubMed] [Google Scholar]
  9. Berm EJ, Looff M, Wilffert B, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One. 2016;11:e0146262. doi: 10.1371/journal.pone.0146262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Brown GC, Brown MM, Lieske HB, et al. A value-based medicine cost-utility analysis of genetic testing for neovascular macular degeneration. Int J Retina Vitr. 2015;1:19. doi: 10.1186/s40942-015-0016-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Brüggenjürgen B, Kornbluth L, Ferrara JV, et al. Herausforderungen an die klinische Evaluation und Gesundheitsökonomie auf dem Weg zur personalisierten Medizin. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2012;55:710–714. doi: 10.1007/s00103-012-1479-2. [DOI] [PubMed] [Google Scholar]
  12. Buchanan J, Wordsworth S, Clifford R, et al. Using genomic information to guide ibrutinib treatment decisions in chronic lymphocytic leukaemia: a cost-effectiveness analysis. PharmacoEconomics. 2017 doi: 10.1007/s40273-017-0519-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cesuroglu T, Syurina E, Feron F, et al. Other side of the coin for personalised medicine and healthcare: content analysis of ‘personalised’ practices in the literature BMJ open. 2016;6:e010243. doi: 10.1136/bmjopen-2015-010243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Chen Y-E, Kao S-S, Chung R-H, Toland AE. Cost-effectiveness analysis of different genetic testing strategies for Lynch syndrome in Taiwan. PLoS One. 2016;11(8):e0160599. doi: 10.1371/journal.pone.0160599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chong HY, Saokaew S, Dumrongprat K, et al. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand. Thromb Res. 2014;134:1278–1284. doi: 10.1016/j.thromres.2014.10.006. [DOI] [PubMed] [Google Scholar]
  16. Coate LE, Leighl NB. How affordable are targeted therapies in non-small cell lung cancer? Curr Treat Options Oncol. 2011;12:1–11. doi: 10.1007/s11864-010-0137-x. [DOI] [PubMed] [Google Scholar]
  17. Conti R, Veenstra DL, Armstrong K, et al. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Mak Int J Soc Med Decis Mak. 2010;30:328–340. doi: 10.1177/0272989X09347014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. D’Andrea E, Marzuillo C, Pelone F, et al. Genetic testing and economic evaluations: a systematic review of the literature. Epidemiol Prev. 2015;39:45–50. [PubMed] [Google Scholar]
  19. D’Andrea E, Marzuillo C, De Vito C, et al. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. Genet Med. 2016;18:1171–1180. doi: 10.1038/gim.2016.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Dong D, Tan-Koi WC, Teng GG, Finkelstein E, Sung C. Cost–effectiveness analysis of genotyping for and an enhanced safety program in gout patients starting allopurinol in Singapore. Pharmacogn. 2015;16(16):1781–1793. doi: 10.2217/pgs.15.125. [DOI] [PubMed] [Google Scholar]
  21. Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015. [Google Scholar]
  22. European Commission . Commission staff working document. Use of “-omics” technologies in the development of personalised medicine. Brussels: European Commission; 2013. [Google Scholar]
  23. Faulkner E, Annemans L, Garrison L, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health J Int Soc Pharmacoecon Outcomes Res. 2012;15:1162–1171. doi: 10.1016/j.jval.2012.05.006. [DOI] [PubMed] [Google Scholar]
  24. Ferrusi IL, Marshall DA, Kulin NA, et al. Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Pers Med. 2009;6:193–215. doi: 10.2217/17410541.6.2.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, Hisama FM, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL. Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis. J Clin Oncol. 2015;33(18):2084–2091. doi: 10.1200/JCO.2014.59.3665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Garrison LP, Jr, Kamal-Bahl S, Towse A. Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis. Value Health J Int Soc Pharmacoecon Outcomes Res. 2017;20:213–216. doi: 10.1016/j.jval.2016.12.005. [DOI] [PubMed] [Google Scholar]
  27. Goldie SJ, Levin AR. Genomics in medicine and public health: role of cost-effectiveness analysis. JAMA. 2001;286:1637–1638. doi: 10.1001/jama.286.13.1637-JMS1003-5-1. [DOI] [PubMed] [Google Scholar]
  28. Gonzalez FM, Veneziano MA, Puggina A, et al. A systematic review on the cost-effectiveness of genetic and electrocardiogram testing for long QT syndrome in infants and young adults. Value Health J Int Soc Pharmacoecon Outcomes Res. 2015;18:700–708. doi: 10.1016/j.jval.2015.03.1788. [DOI] [PubMed] [Google Scholar]
  29. Goverde A, Spaander MCW, van Doorn HC, Dubbink HJ, van den Ouweland AMW, Tops CM, Kooi SG, de Waard J, Hoedemaeker RF, Bruno MJ, Hofstra RMW, de Bekker-Grob EW, Dinjens WNM, Steyerberg EW, Wagner A. Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70 years of age. Gynecol Oncol. 2016;143(3):453–459. doi: 10.1016/j.ygyno.2016.10.008. [DOI] [PubMed] [Google Scholar]
  30. Green LE, Dinh TA, Hinds DA, et al. Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy. Appl Health Econ Health Policy. 2014;12:203–217. doi: 10.1007/s40258-014-0089-6. [DOI] [PubMed] [Google Scholar]
  31. Grosse SD. When is genomic testing cost-effective? Testing for lynch syndrome in patients with newly-diagnosed colorectal cancer and their relatives. Healthcare. 2015;3:860–878. doi: 10.3390/healthcare3040860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Grosse SD, Wordsworth S, Payne K. Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med. 2008;10:648–654. doi: 10.1097/GIM.0b013e3181837217. [DOI] [PubMed] [Google Scholar]
  33. Hatz MH, Schremser K, Rogowski WH. Is individualized medicine more cost-effective? A systematic review. PharmacoEconomics. 2014;32:443–455. doi: 10.1007/s40273-014-0143-0. [DOI] [PubMed] [Google Scholar]
  34. Horster L, Schlenk RF, Stadler M, et al. Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. Leuk Res. 2017;62:84–90. doi: 10.1016/j.leukres.2017.09.009. [DOI] [PubMed] [Google Scholar]
  35. Husereau D, Marshall DA, Levy AR, et al. Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making? Int J Technol Assess Health Care. 2014;30:179–187. doi: 10.1017/S0266462314000142. [DOI] [PubMed] [Google Scholar]
  36. Institute of Medicine . The economics of genomic medicine: workshop summary. Washington, DC: National Academies Press; 2013. [PubMed] [Google Scholar]
  37. Jahn B, Rochau U, Kurzthaler C, et al. Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria. SpringerPlus. 2015;4:752. doi: 10.1186/s40064-015-1440-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Jahn B, Rochau U, Kurzthaler C, et al. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. BMC Cancer. 2017;17:685. doi: 10.1186/s12885-017-3603-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ke CH, Chung WH, Wen YH, et al. Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol. 2017;44:835–843. doi: 10.3899/jrheum.151476. [DOI] [PubMed] [Google Scholar]
  40. Lazaro P, Perez de Isla L, Watts GF, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol. 2017;11:260–271. doi: 10.1016/j.jacl.2017.01.002. [DOI] [PubMed] [Google Scholar]
  41. Lee WS, Palmer BJ, Garcia A, et al. BRAF mutation in papillary thyroid cancer: a cost-utility analysis of preoperative testing. Surgery. 2014;156:1569–1577. doi: 10.1016/j.surg.2014.08.051. [DOI] [PubMed] [Google Scholar]
  42. Li Y, Arellano AR, Bare LA, Bender RA, Strom CM, Devlin JJ. A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer. Value Health. 2017;20(4):547–555. doi: 10.1016/j.jval.2017.01.006. [DOI] [PubMed] [Google Scholar]
  43. Lieberthal RD. Economics of genomic testing for women with breast cancer. Am J Managed Care. 2013;19:1024–1031. [PubMed] [Google Scholar]
  44. Lim EA, Lee H, Bae E, et al. Economic evaluation of companion diagnostic testing for EGFR mutations and first-line targeted therapy in advanced non-small cell lung cancer patients in South Korea. PLoS ONE. 2016;11:e0160155. doi: 10.1371/journal.pone.0160155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Lu S, Zhang J, Ye M, Wang B, Wu B. Economic analysis of testing and crizotinib therapy for advanced non-small-cell lung cancer. Pharmacogn. 2016;17(9):985–994. doi: 10.2217/pgs-2016-0017. [DOI] [PubMed] [Google Scholar]
  46. Manchanda R, Legood R, Burnell M, et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J Natl Cancer Inst. 2015;107:380. doi: 10.1093/jnci/dju380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Martes-Martinez C, Mendez-Sepulveda C, Millan-Molina J, et al. Cost-utility study of warfarin genotyping in the VACHS affiliated anticoagulation clinic of Puerto Rico. Puerto Rico Health Sci J. 2017;36:165–172. [PMC free article] [PubMed] [Google Scholar]
  48. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Moretti ME, Lato DF, Berger H, et al. A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events. Pharmacogenom J. 2017 doi: 10.1038/tpj.2017.33. [DOI] [PubMed] [Google Scholar]
  50. National Institute of Health NIH (2016) The cost of sequencing a human genome. https://www.genome.gov/27565109/the-cost-of-sequencing-a-human-genome/. Accessed 4 Dec 2017
  51. Narita Y, Matsushima Y, Shiroiwa T, Chiba K, Nakanishi Y, Kurokawa T, Urushihara H. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. Lung Cancer. 2015;90(1):71–77. doi: 10.1016/j.lungcan.2015.07.006. [DOI] [PubMed] [Google Scholar]
  52. Naylor RN, John PM, Winn AN, et al. Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014;37:202–209. doi: 10.2337/dc13-0410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. NCBI. GTR: Genetic Testing Registry (2017) GTR data. NCBI. https://www.ncbi.nlm.nih.gov/gtr/. Accessed 3 Dec 2017
  54. Nguyen HV, Finkelstein EA, Mital S, et al. Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore. J Med Genet. 2017;54:747–753. doi: 10.1136/jmedgenet-2017-104670. [DOI] [PubMed] [Google Scholar]
  55. Nimmesgern E, Benediktsson I, Norstedt I. Personalized medicine in Europe. Clin Transl Sci. 2017;10:61–63. doi: 10.1111/cts.12446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Patel V, Lin FJ, Ojo O, Rao S, Yu S, Zhan L, Touchette DR. Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharm Pract (Granada) 2014;12(3):438. doi: 10.4321/S1886-36552014000300007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Patrinos GP, Mitropoulou C. Measuring the value of pharmacogenomics evidence. Clin Pharmacol Ther. 2017;102:739–741. doi: 10.1002/cpt.743. [DOI] [PubMed] [Google Scholar]
  58. Phillips KA, Ann Sakowski J, Trosman J, et al. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014;16:251–257. doi: 10.1038/gim.2013.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Pink J, Pirmohamed M, Lane S, et al. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther. 2014;95:199–207. doi: 10.1038/clpt.2013.190. [DOI] [PubMed] [Google Scholar]
  60. Plothner M, Ribbentrop D, Hartman JP, et al. Cost-effectiveness of pharmacogenomic and pharmacogenetic test-guided personalized therapies: a systematic review of the approved active substances for personalized medicine in Germany. Adv Ther. 2016;33:1461–1480. doi: 10.1007/s12325-016-0376-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Plumpton CO, Yip VL, Alfirevic A, et al. Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia. 2015;56:556–563. doi: 10.1111/epi.12937. [DOI] [PubMed] [Google Scholar]
  62. Plumpton CO, Roberts D, Pirmohamed M, et al. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. PharmacoEconomics. 2016;34:771–793. doi: 10.1007/s40273-016-0397-9. [DOI] [PubMed] [Google Scholar]
  63. Ross S, Anand SS, Joseph P, et al. Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis. 2012;1:15. doi: 10.1258/cvd.2012.012001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Rosso A, Pitini E, D’Andrea E, et al. The cost-effectiveness of genetic screening for familial hypercholesterolemia: a systematic review. Ann Ig Med Prev Comunita. 2017;29:464–480. doi: 10.7416/ai.2017.2178. [DOI] [PubMed] [Google Scholar]
  65. Rubio-Terres C, Soria JM, Morange PE, et al. Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism. Appl Health Econ Health Policy. 2015;13:233–242. doi: 10.1007/s40258-015-0153-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Ruiz-Iruela C, Padulles-Zamora N, Podzamczer-Palter D, et al. HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience. Pharmacogenet Genom. 2016;26:390–396. doi: 10.1097/fpc.0000000000000229. [DOI] [PubMed] [Google Scholar]
  67. Saokaew S, Tassaneeyakul W, Maenthaisong R, et al. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population. PLoS One. 2014;9:e94294. doi: 10.1371/journal.pone.0094294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Schackman BR, Haas DW, Park SS, Cynthia Li X, Freedberg KA. Cost–effectiveness of genotyping to optimize efavirenz dosing in HIV clinical practice. Pharmacogenomics. 2015;16(18):2007–2018. doi: 10.2217/pgs.15.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Schremser K, Rogowski WH, Adler-Reichel S, et al. Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on egfr mutation testing in advanced lung adenocarcinoma patients in Germany. PharmacoEconomics. 2015;33:1215–1228. doi: 10.1007/s40273-015-0305-8. [DOI] [PubMed] [Google Scholar]
  70. Shabaruddin FH, Fleeman ND, Payne K. Economic evaluations of personalized medicine: existing challenges and current developments. Pharmgenom Pers Med. 2015;8:115–126. doi: 10.2147/PGPM.S35063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Shiffman D, Perez MV, Bare LA, et al. Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis. BMC Cardiovasc disord. 2015;15:104. doi: 10.1186/s12872-015-0100-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol Assess. 2014;18(58):1–406. doi: 10.3310/hta18580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C. A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer. 2015;15:313. doi: 10.1186/s12885-015-1254-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Snowsill T, Coelho H, Huxley N, et al. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technol Assess. 2017;21:1–238. doi: 10.3310/hta21510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Terkola R, Antonanzas F, Postma M. Economic evaluation of personalized medicine: a call for real-world data. Eur J Health Econ. 2017 doi: 10.1007/s10198-017-0890-x. [DOI] [PubMed] [Google Scholar]
  76. U.S. National Library of Medicine (2017) Medical subjects heading (MeSH). Precision medicine MeSH descriptor data 2017. National Institute of Health (NIH). https://meshb.nlm.nih.gov/record/ui?ui=D057285. Accessed 19 Sept 2017
  77. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2000;2:80–90. doi: 10.1208/ps020329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Vegter S, Jansen E, Postma MJ, et al. Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature. Drug Dev Res. 2010;71:492–501. doi: 10.1002/ddr.20424. [DOI] [Google Scholar]
  79. Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenom J. 2017;17:395–402. doi: 10.1038/tpj.2017.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Verhoef TI, Redekop WK, Langenskiold S, et al. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenom J. 2016;16:478–484. doi: 10.1038/tpj.2016.41. [DOI] [PubMed] [Google Scholar]
  81. Waldman SA, Terzic A. Pharmacoeconomics in the era of individualized medicine. Clin Pharmacol Ther. 2008;84:179–182. doi: 10.1038/clpt.2008.142. [DOI] [PubMed] [Google Scholar]
  82. Wallbillich JJ, Forde B, Havrilesky LJ, Cohn DE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer – a cost utility analysis of genomic-based versus cytotoxic therapy. Gynecol Oncol. 2016;142(1):144–149. doi: 10.1016/j.ygyno.2016.04.024. [DOI] [PubMed] [Google Scholar]
  83. Wang Y, Yan BP, Liew D, et al. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. Pharmacogenom J. 2017 doi: 10.1038/tpj.2016.94. [DOI] [PubMed] [Google Scholar]
  84. Wong WB, Carlson JJ, Thariani R, et al. Cost effectiveness of pharmacogenomics: a critical and systematic review. PharmacoEconomics. 2010;28:1001–1013. doi: 10.2165/11537410-000000000-00000. [DOI] [PubMed] [Google Scholar]
  85. Yamauchi H, Nakagawa C, Yamashige S, Takei H, Yagata H, Yoshida A, Hayashi N, Hornberger J, Yu T, Chao C, Yoshizawa C, Nakamura S (2014) Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stagebreast cancer in Japan. BMC Health Services Research 14(1) [DOI] [PMC free article] [PubMed]
  86. You JH. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis. Pharmacogn Genom. 2014;24:6–14. doi: 10.1097/FPC.0000000000000014. [DOI] [PubMed] [Google Scholar]
  87. You JH. Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics. 2015;16(10):1089–1100. doi: 10.2217/pgs.15.64. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material 1 (PDF 132 kb) (132.3KB, pdf)

Articles from International Journal of Public Health are provided here courtesy of Springer

RESOURCES